Each of the CG genes (MAGEA1, NY-ESO1, and XAGE1) that James et al. assessed was not substantially expressed in benign prostate cell lines but was heterogeneously expressed in prostate cancer cell lines [24]. The gene discussed is XAGE1A; the disease is medical procedure.